Phase II trial of pegylated liposomal doxorubicin (Doxil), vincristine, and dexamethasone (DVd) in combination with arsenic trioxide (Trisenox) in untreated patients with symptomatic multiple myeloma.

Trial Profile

Phase II trial of pegylated liposomal doxorubicin (Doxil), vincristine, and dexamethasone (DVd) in combination with arsenic trioxide (Trisenox) in untreated patients with symptomatic multiple myeloma.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jun 2015

At a glance

  • Drugs Arsenic trioxide (Primary) ; Dexamethasone; Doxorubicin liposomal; Vincristine
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 May 2012 Additional lead trial investigator (Hofmeister C) added as reported by ClinicalTrials.gov.
    • 09 Nov 2011 Actual end date (August 2008) added as reported by ClinicalTrials.gov.
    • 09 Nov 2011 Status changed from suspended to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top